A Phase II Study of 131I-rituximab for Patients With Relapsed or Refractory Marginal Zone Lymphoma.
Jang YJ, Lim SM, Lee I, Byun BH, Lim I, Kim BI, Choi CW, Lee SS, Yang SH, Na II, Lee HR, Shin DY, Kang HJ.
Jang YJ, et al.
Clin Med Insights Oncol. 2023 Dec 11;17:11795549231218082. doi: 10.1177/11795549231218082. eCollection 2023.
Clin Med Insights Oncol. 2023.
PMID: 38090634
Free PMC article.